Search
Substances of Human Origin (SoHO) legislation
EHA’s involvementEHA has been involved in both the evaluation and subsequent revision of the EU legislation on human blood and blood components. The evaluation of these rules, which dated back to 2002, began in 2016.
Read moreEHA Kick-off Grants
The call for applications is closed. The EHA Kick-off Grant is a one-year grant intended to support basic and translational early career researchers in hematology.
Read moreTraining vital for new era of patient-centric healthcare
Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…
Read moreHighlights from the SWG
EventsParticipation in the 19th European LeukemiaNet (ELN) SymposiumLocation and dateThis event was held in Mannheim, Germany, on April 18, 2023. Chairs
D. Hoelzer
S. Chiaretti
Topics
Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands). Inotuzumab ozogamicin in MRD+ ALL (G.
EHA leads Tutorial in Kazakhstan for better understanding of lymphomas
EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.
Read moreEU Elections and Health Policy
HemAffairs Article #1 – June 2019
2019 will see significant changes within the European institutions.
The European Union must deliver funding for research of blood disorders
At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.
Read moreEHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Read moreHighlights from the SWG
SWG Session at EHA2023ELN-EHA SWG for CML: CML: modelling the futureChairJane Apperley (United Kingdom)
Topics and presenters
Identifying new targets for BCR::ABL1 inhibition: Oliver Hantschel (Germany). Dissecting phylogenetic trees in CML: Aleksandra Kamizela (United Kingdom).
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- »